Insmed Incorporated (INSM:NASDAQ) closed at $114.41 on November 6, 2026, up 5.19% on the day. The stock trades 46.2% below its 52-week high of $212.75 and 26.6% above its 52-week low of $90.39. Over the past year, it lost 39.7%. Insmed Incorporated is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, INSM closed higher on 117 days (46%). Its best day was August 6, 2026 (+33.86%) and its worst was May 7, 2026 (-23.41%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 3 times.
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Find more stocks like INSM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.